Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021

March 8, 2022, Vol 327, No. 10, Pages 897-1003


Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021
Caroline L. Behr, AB; Karen E. Joynt Maddox, MD, MPH; Ellen Meara, PhD; et al.
free access has active quiz
JAMA. 2022;327(10):980-983. doi:10.1001/jama.2022.1243
This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.

Long-Acting Cabotegravir for HIV PreventionIssues of Access, Cost, and Equity
Joshua M. Sharfstein, MD; Amy Killelea, JD; Derek Dangerfield, PhD
free access
JAMA. 2022;327(10):921-922. doi:10.1001/jama.2022.0420
This Viewpoint discusses the recent FDA approval of cabotegravir, the first injectable medication to help prevent HIV infection, and how its effectiveness may be complicated by the cost and complexity of the US health care system.